Gilead Sciences, Inc.- Company Snapshot & SWOT Analysis
Gilead Sciences, Inc. (Gilead) is a U.S. based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Gilead’s primary areas of focus include HIV/AIDS, liver diseases, hematology/oncology and inflammation/respiratory diseases.
Gilead Sciences registered profit in the fourth quarter from a loss last year, helped by a push in income taxes provision.
Company's 2018 Revenue declined 2.6% to USD 5.8 billion. The results reflected by lower product sales in Europe and in other regions. Chronic hepatitis C virus franchise sales plunged 50.8% due to lower average selling price and lower sales volume of Harvoni and Epclusa across all major markets as a result of increased generic competition and the lower patient engagement.
For the fourth quarter, R&D expenses increased by 69.6% Y-O-Y. This was primarily due to an impairment charge related to in-process R&D for multiple myeloma treating program, up-front collaboration expenses and higher investments to support the growth of Gilead’s business following the acquisition of Kite.
Spanning over 30 pages and 18 exhibits, “Gilead Sciences, Inc. - Company Snapshot & SWOT Analysis” report provides value chain analysis, financial performance, business strategy and SWOT analysis for company.
Scope of the Gilead Sciences, Inc.- Company Snapshot & SWOT Analysis Report
Gilead Sciences registered profit in the fourth quarter from a loss last year, helped by a push in income taxes provision.
Company's 2018 Revenue declined 2.6% to USD 5.8 billion. The results reflected by lower product sales in Europe and in other regions. Chronic hepatitis C virus franchise sales plunged 50.8% due to lower average selling price and lower sales volume of Harvoni and Epclusa across all major markets as a result of increased generic competition and the lower patient engagement.
For the fourth quarter, R&D expenses increased by 69.6% Y-O-Y. This was primarily due to an impairment charge related to in-process R&D for multiple myeloma treating program, up-front collaboration expenses and higher investments to support the growth of Gilead’s business following the acquisition of Kite.
Spanning over 30 pages and 18 exhibits, “Gilead Sciences, Inc. - Company Snapshot & SWOT Analysis” report provides value chain analysis, financial performance, business strategy and SWOT analysis for company.
Scope of the Gilead Sciences, Inc.- Company Snapshot & SWOT Analysis Report
- This report provides detailed information about Gilead Sciences, Inc. including value chain analysis, financial performance, business strategy and SWOT analysis.
- The report identifies the growth drivers and inhibitors for global pharmaceutical market.
- This report provides information about current and future trends for global pharmaceutical market.
1. EXECUTIVE SUMMARY
Scope of the Gilead Sciences, Inc.- Company Snapshot & SWOT Analysis Report
Research Methodology
2. GROWTH DRIVERS AND INHIBITORS FOR GLOBAL PHARMACEUTICALS MARKET
3. COMPANY PROFILE
3.1 Gilead Sciences Inc.
3.1.1. Company Profile
3.1.2 Gilead Sciences, Inc. in Global Pharmaceuticals Manufacturing Value Chain
3.1.3 Gilead Sciences, Inc.: Financial Performance
3.1.4 Gilead Sciences, Inc.: Geography wise Performance
3.1.5 Gilead Sciences, Inc.: Business Strategy
3.1.5.1 Gilead Sciences, Inc. Revenue by Business Segment
3.1.6 SWOT Analysis of Gilead Sciences, Inc.
Strengths
Weaknesses
Opportunities
Threats
4. CURRENT AND FUTURE TRENDS IN PHARMACEUTICAL MARKET
Orphan Drugs
Biologics and Biosimilars
Current Trends
Company Information
Scope of the Gilead Sciences, Inc.- Company Snapshot & SWOT Analysis Report
Research Methodology
2. GROWTH DRIVERS AND INHIBITORS FOR GLOBAL PHARMACEUTICALS MARKET
3. COMPANY PROFILE
3.1 Gilead Sciences Inc.
3.1.1. Company Profile
3.1.2 Gilead Sciences, Inc. in Global Pharmaceuticals Manufacturing Value Chain
3.1.3 Gilead Sciences, Inc.: Financial Performance
3.1.4 Gilead Sciences, Inc.: Geography wise Performance
3.1.5 Gilead Sciences, Inc.: Business Strategy
3.1.5.1 Gilead Sciences, Inc. Revenue by Business Segment
3.1.6 SWOT Analysis of Gilead Sciences, Inc.
Strengths
Weaknesses
Opportunities
Threats
4. CURRENT AND FUTURE TRENDS IN PHARMACEUTICAL MARKET
Orphan Drugs
Biologics and Biosimilars
Current Trends
Company Information
LIST OF EXHIBITS
Exhibit 2.1 Growth Drivers and Inhibitors for Global Pharmaceuticals Market
Exhibit 3.1 Key Information of Gilead Sciences, Inc.
Exhibit 3.2 Contact Information of Gilead Sciences, Inc.
Exhibit 3.3 Gilead Sciences, Inc. in Global Pharmaceuticals Manufacturing Value Chain
Exhibit 3.4 Gilead Sciences, Inc. Revenue 2014-2019 (in USD billion)
Exhibit 3.5 Year-wise Gilead Sciences, Inc. Revenue Growth 2014-19 (in %)
Exhibit 3.6 Gilead Sciences, Inc. Geography Wise Revenue Share in (%) 2018
Exhibit 3.7 Gilead Sciences, Inc. Geography Wise Revenue in USD Billion (2016 - 2018)
Exhibit 3.8 Gilead Sciences, Inc. Business Segment Revenue Share 2018
Exhibit 3.9 Gilead Sciences, Inc. Segment wise Revenue in USD Billion (2016- 2018)
Exhibit 3.10 Gilead Sciences, Inc. Revenue from HIV Product Sales (2016-2018)
Exhibit 3.11 Gilead Sciences, Inc. HIV Product Sales by Medicine in USD Million (2018)
Exhibit 3.12 Gilead Sciences, Inc. Revenue from HCV Product Sales (2016-2018)
Exhibit 3.13 Gilead Sciences, Inc. HCV Product Sales by Medicine in USD Million (2018)
Exhibit 3.14 Gilead Sciences, Inc. Revenue from HBV, Cardio, Oncology and Others Product Sales (2016-2018)
Exhibit 3.15 Gilead Sciences, Inc. Revenue from HBV, Cardio, Oncology and Others Product Sales by Medicine in USD Million (2018)
Exhibit 3.16 Gilead Sciences, Inc. Revenue from Yescarta® Sales (2017-2018)
Exhibit 3.17 SWOT Analysis of Gilead Sciences, Inc.
Exhibit 2.1 Growth Drivers and Inhibitors for Global Pharmaceuticals Market
Exhibit 3.1 Key Information of Gilead Sciences, Inc.
Exhibit 3.2 Contact Information of Gilead Sciences, Inc.
Exhibit 3.3 Gilead Sciences, Inc. in Global Pharmaceuticals Manufacturing Value Chain
Exhibit 3.4 Gilead Sciences, Inc. Revenue 2014-2019 (in USD billion)
Exhibit 3.5 Year-wise Gilead Sciences, Inc. Revenue Growth 2014-19 (in %)
Exhibit 3.6 Gilead Sciences, Inc. Geography Wise Revenue Share in (%) 2018
Exhibit 3.7 Gilead Sciences, Inc. Geography Wise Revenue in USD Billion (2016 - 2018)
Exhibit 3.8 Gilead Sciences, Inc. Business Segment Revenue Share 2018
Exhibit 3.9 Gilead Sciences, Inc. Segment wise Revenue in USD Billion (2016- 2018)
Exhibit 3.10 Gilead Sciences, Inc. Revenue from HIV Product Sales (2016-2018)
Exhibit 3.11 Gilead Sciences, Inc. HIV Product Sales by Medicine in USD Million (2018)
Exhibit 3.12 Gilead Sciences, Inc. Revenue from HCV Product Sales (2016-2018)
Exhibit 3.13 Gilead Sciences, Inc. HCV Product Sales by Medicine in USD Million (2018)
Exhibit 3.14 Gilead Sciences, Inc. Revenue from HBV, Cardio, Oncology and Others Product Sales (2016-2018)
Exhibit 3.15 Gilead Sciences, Inc. Revenue from HBV, Cardio, Oncology and Others Product Sales by Medicine in USD Million (2018)
Exhibit 3.16 Gilead Sciences, Inc. Revenue from Yescarta® Sales (2017-2018)
Exhibit 3.17 SWOT Analysis of Gilead Sciences, Inc.
